These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 17486678)

  • 41. Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder.
    Papakostas GI; McGrath P; Stewart J; Charles D; Chen Y; Mischoulon D; Dording C; Fava M
    Psychiatry Res; 2008 Oct; 161(1):116-20. PubMed ID: 18755514
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sex- and age-related differences in major depressive disorder with comorbid anxiety treated with fluoxetine.
    Cassano P; Soares CN; Cohen LS; Lyster AK; Fava M
    Arch Womens Ment Health; 2004 Jul; 7(3):167-71. PubMed ID: 15241662
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A double-blind, placebo-controlled treatment trial of citalopram for major depressive disorder in older patients with heart failure: the relevance of the placebo effect and psychological symptoms.
    Fraguas R; da Silva Telles RM; Alves TC; Andrei AM; Rays J; Iosifescu DV; Wajngarten M
    Contemp Clin Trials; 2009 May; 30(3):205-11. PubMed ID: 19470312
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anhedonia among patients with Major Depressive Disorder: A comparison between patients on escitalopram and healthy controls.
    Ng CG; Wong SK; Loh HS; Yee A
    Clin Ter; 2014; 165(6):e384-90. PubMed ID: 25524191
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Symptom clusters as predictors of late response to antidepressant treatment.
    Trivedi MH; Morris DW; Grannemann BD; Mahadi S
    J Clin Psychiatry; 2005 Aug; 66(8):1064-70. PubMed ID: 16086624
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Quality of Life, Functioning, and Depressive Symptom Severity in Older Adults With Major Depressive Disorder Treated With Citalopram in the STAR*D Study.
    Steiner AJ; Recacho J; Vanle B; Dang J; Wright SM; Miller JS; Kauzor K; Reid M; Bashmi LE; Mirocha J; Danovitch I; IsHak WW
    J Clin Psychiatry; 2017 Jul; 78(7):897-903. PubMed ID: 28858443
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Correlates and outcomes of depressed out-patients with greater and fewer anxious symptoms: a CO-MED report.
    Chan HN; Rush AJ; Nierenberg AA; Trivedi M; Wisniewski SR; Balasubramani GK; Friedman ES; Gaynes BN; Davis L; Morris D; Fava M
    Int J Neuropsychopharmacol; 2012 Nov; 15(10):1387-99. PubMed ID: 22129562
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Use of Machine Learning for Predicting Escitalopram Treatment Outcome From Electroencephalography Recordings in Adult Patients With Depression.
    Zhdanov A; Atluri S; Wong W; Vaghei Y; Daskalakis ZJ; Blumberger DM; Frey BN; Giacobbe P; Lam RW; Milev R; Mueller DJ; Turecki G; Parikh SV; Rotzinger S; Soares CN; Brenner CA; Vila-Rodriguez F; McAndrews MP; Kleffner K; Alonso-Prieto E; Arnott SR; Foster JA; Strother SC; Uher R; Kennedy SH; Farzan F
    JAMA Netw Open; 2020 Jan; 3(1):e1918377. PubMed ID: 31899530
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Apathy in late-life depression: common, persistent, and disabling.
    Yuen GS; Bhutani S; Lucas BJ; Gunning FM; AbdelMalak B; Seirup JK; Klimstra SA; Alexopoulos GS
    Am J Geriatr Psychiatry; 2015 May; 23(5):488-94. PubMed ID: 25047306
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cognitive-functional relationships in major depressive disorder: Crucial data from a Ukrainian open-label study of vortioxetine versus escitalopram.
    Levada OA; Troyan AS
    J Affect Disord; 2019 May; 250():114-122. PubMed ID: 30852363
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Predicting relapse in major depressive disorder using patient-reported outcomes of depressive symptom severity, functioning, and quality of life in the Individual Burden of Illness Index for Depression (IBI-D).
    Ishak WW; Greenberg JM; Cohen RM
    J Affect Disord; 2013 Oct; 151(1):59-65. PubMed ID: 23790554
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Influence of anxiety symptoms on improvement of neurocognitive functions in patients with major depressive disorder: A 12-week, multicenter, randomized trial of tianeptine versus escitalopram, the CAMPION study.
    Yoo I; Woo JM; Lee SH; Fava M; Mischoulon D; Papakostas GI; Kim EJ; Chung S; Ha JH; Jeon HJ
    J Affect Disord; 2015 Oct; 185():24-30. PubMed ID: 26142691
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Short-term escitalopram treatment normalizes aberrant self-referential processing in major depressive disorder.
    Komulainen E; Heikkilä R; Nummenmaa L; Raij TT; Harmer CJ; Isometsä E; Ekelund J
    J Affect Disord; 2018 Aug; 236():222-229. PubMed ID: 29747140
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Escitalopram plasma levels and antidepressant response.
    Florio V; Porcelli S; Saria A; Serretti A; Conca A
    Eur Neuropsychopharmacol; 2017 Sep; 27(9):940-944. PubMed ID: 28648553
    [TBL] [Abstract][Full Text] [Related]  

  • 55. MRI signal hyperintensities and treatment remission of geriatric depression.
    Gunning-Dixon FM; Walton M; Cheng J; Acuna J; Klimstra S; Zimmerman ME; Brickman AM; Hoptman MJ; Young RC; Alexopoulos GS
    J Affect Disord; 2010 Nov; 126(3):395-401. PubMed ID: 20452031
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment with escitalopram improves the attentional bias toward negative facial expressions in patients with major depressive disorders.
    Zhou Z; Cao S; Li H; Li Y
    J Clin Neurosci; 2015 Oct; 22(10):1609-13. PubMed ID: 26149404
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cognitive and psychomotor effects of three months of escitalopram treatment in elderly patients with major depressive disorder.
    Beheydt LL; Schrijvers D; Docx L; Bouckaert F; Hulstijn W; Sabbe B
    J Affect Disord; 2015 Dec; 188():47-52. PubMed ID: 26342888
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Psychosocial functioning during the treatment of major depressive disorder with fluoxetine.
    Papakostas GI; Petersen T; Denninger JW; Tossani E; Pava JA; Alpert JE; Nierenberg AA; Fava M
    J Clin Psychopharmacol; 2004 Oct; 24(5):507-11. PubMed ID: 15349006
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cognitive control, reward-related decision making and outcomes of late-life depression treated with an antidepressant.
    Alexopoulos GS; Manning K; Kanellopoulos D; McGovern A; Seirup JK; Banerjee S; Gunning F
    Psychol Med; 2015 Oct; 45(14):3111-20. PubMed ID: 26169527
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical and functional outcomes of patients who experience partial response to citalopram: secondary analysis of STAR*D.
    Dennehy EB; Marangell LB; Martinez J; Balasubramani GK; Wisniewski SR
    J Psychiatr Pract; 2014 May; 20(3):178-87. PubMed ID: 24847991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.